Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences.

Despite recent approvals of lifesaving treatments for chronic lymphocytic leukemia (CLL), real-world data on the tolerability of the Bruton tyrosine kinase inhibitor ibrutinib for CLL treatment are lacking, especially in Black patients. To expand upon a previously reported retrospective chart review of ibrutinib-treated patients with CLL to increase the number of sites and the enrollment period in first-line (1L) and relapsed/refractory (R/R) settings with a subanalysis based on ethnicity. Adults with CLL who initiated ibrutinib treatment from five centers were followed for ≥ 6 months. We identified 482 patients with CLL [405 White (153 1L, 252 R/R), 37 Black (17 1L, 20 R/R), 40 other/unidentified]. At baseline, 58.5% of all patients (68.8% of Black patients) had hypertension. At a median follow-up of 28.2 months, 31.1% of patients overall discontinued ibrutinib, 16.2% due to adverse events (12.2% 1L, 18.8% R/R). Overall, 46.0% of patients experienced ≥ 1 dose hold (40.2% 1L, 49.8% R/R), and 28.8% of patients experienced ≥ 1 dose reduction (24.9% 1L, 31.4% R/R). Among Black patients, ibrutinib was discontinued in 24.3% of patients (17.6% 1L, 30.0% R/R), 8.1% due to disease progression and 5.4% due to adverse events; 40.5% of patients experienced ≥ 1 dose hold (35.3% 1L, 45.0% R/R), and 32.4% of patients experienced ≥ 1 dose reduction (23.5% 1L, 40.0% R/R). Toxicity and disease progression were the most common reasons for ibrutinib discontinuations in the overall population and among Black patients, respectively. Encouraging research participation of underrepresented patient groups will help clinicians better understand treatment outcomes.

Barrientos JC ，Ayed AO ，Cha A ，Du S ，Fang B ，Hall R ，Marks SM ，Peng E ，Rhodes JM ，Ryan K ，Winters SB ，Yeung PL ，Hou JZ ... -  《-》

Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.

Hou JZ ，Ryan K ，Du S ，Fang B ，Marks S ，Page R ，Peng E ，Szymanski K ，Winters S ，Le H ... -  《-》

Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study.

Moldovianu AM ，Stoia R ，Vasilica M ，Ursuleac I ，Badelita SN ，Tomescu AA ，Preda OD ，Bardas A ，Cirstea M ，Coriu D ... -  《-》

Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis.

Huang Q ，Borra S ，Li J ，Wang L ，Shrestha S ，Sundaram M ，Janjan N ... -  《-》

Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib.

Jacobs R ，Lu X ，Emond B ，Morrison L ，Kinkead F ，Lefebvre P ，Lafeuille MH ，Khan W ，Wu LH ，Qureshi ZP ，Levy MY ... -  《-》